References
- World Cancer Research Fund. Colorectal cancer statistics (2018). https://www.wcrf.org/dietandcancer/cancer-trends/colorectal-cancer-statistics ( Accessed August 2022).
- FerraraN, GerberHP, LeCouterJ. The biology of VEGF and its receptors. Nat. Med.9, 669–676 (2003).
- NiuG, ChenX. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr. Drug Targets11, 1000–1017 (2010).
- RosenLS, JacobsIA, BurkesRL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol.12, 599–610 (2017).
- Genentech Inc. Avastin® Prescribing Information (2020). https://www.gene.com/download/pdf/avastin_prescribing.pdf ( Accessed August 2022).
- RochePharma AG. Avastin® Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf ( Accessed August 2022).
- HurwitzH, FehrenbacherL, NovotnyWet al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
- SaltzLB, ClarkeS, Diaz-RubioEet al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol.26, 2013–2019 (2008).
- Van CutsemE, RiveraF, BerrySet al.Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol.20, 1842–1847 (2009).
- GiantonioBJ, CatalanoPJ, MeropolNJet al.Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25, 1539–1544 (2007).
- BennounaJ, BorgC, DelordJPet al.Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin. Colorectal Cancer11, 38–44 (2012).
- BotrelTEA, ClarkLGO, PaladiniLet al.Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer16, 677 (2016).
- BupathiM, AhnDH, Bekaii-SaabT. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest. Cancer6, 21–30 (2016).
- JangHJ, KimBJ, KimJHet al.The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget8, 73009–73016 (2017).
- CunninghamD, WongRP, D′HaensGet al.Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br. J. Cancer108, 493–502 (2013).
- HechtJR, MitchellE, ChidiacTet al.A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27, 672–680 (2009).
- HochsterHS, HartLL, RamanathanRKet al.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol.26, 3523–3529 (2008).
- SchmollHJ, CunninghamD, SobreroAet al.Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J. Clin. Oncol.30, 3588–3595 (2012).
- SchwartzbergLS, RiveraF, KarthausMet al.PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol.32, 2240–2247 (2014).
- ChioreanEG, NandakumarG, FadeluTet al.Treatment of patients with late-stage colorectal cancer: ASCO Resource-Stratified Guideline. JCO Global Oncology6, 414–438 (2020).
- Van CutsemE, CervantesA, AdamRet al.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol.27, 1386–1422 (2016).
- RiveraF, KarthausM, HechtJRet al.Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int. J. Colorectal Dis.32, 1179–1190 (2017).
- SaltzL, BadarinathS, DakhilSet al.Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin. Colorectal Cancer11, 101–111 (2012).
- Amgen Inc. Mvasi® US prescribing information (2021). https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/mvasi/mvasi_pi_hcp_english.pdf ( Accessed September 2021).
- Amgen Inc. Mvasi® EU summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/mvasi-epar-product-information_en.pdf ( Accessed September 2021).
- Pfizer Inc. Zirabev® EU Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/zirabev-epar-product-information_en.pdf ( Accessed September 2021).
- HettemaW, WynneC, LangBet al.A randomized, single-blind, phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opin. Investig. Drugs26, 889–896 (2017).
- VenookAP, NiedzwieckiD, LenzHJet al.Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA317, 2392–2401 (2017).
- CercekA, BraghiroliMI, ChouJFet al.Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clin. Cancer Res.23, 4753–4760 (2017).
- LuJF, BrunoR, EpplerSet al.Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol.62, 779–786 (2008).
- US FDA. Scientific considerations in demonstrating biosimilarity to a reference product (2015). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product ( Accessed November 2021).
- CremoliniC, AntoniottiC, LonardiSet al.Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann. Oncol.29, 1528–1534 (2018).
- LoupakisF, HurwitzHI, SaltzLet al.Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. Br. J. Cancer119, 1451–1455 (2018).
- ArnoldD, LuezaB, DouillardJYet al.Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol.28, 1713–1729 (2017).